Enjoy the benefits at Opiant. Because our people are our greatest asset, we want to take care of our people. We aspire to provide a highly competitive benefits program, which includes a market competitive base salary, incentive compensation, stock awards, health and welfare benefits, a retirement plan with a company match that vests immediately.
Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat after the company reported Q4 results. Quarterly Results Earnings per share decreased 180.00% over the past year to ($0.16), which missed
About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com. Forward-Looking Statements This press release contains forward-looking statements. 2020-05-12 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit Indication Program / Regulatory Pathway Preclinical Phase I Phase II Phase III NDA FDA Approval Partner; Opioid Overdose: NARCAN® Nasal Spray: Approved: Opioid Overdose NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4 2020-10-29 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. 2021-03-15 · View the latest Opiant Pharmaceuticals Inc. (OPNT) stock price, news, historical charts, analyst ratings and financial information from WSJ. 2021-04-05 · About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
, March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose SANTA MONICA, Calif. , March 31, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions… 2020-12-10 · Opiant Pharmaceuticals News: This is the News-site for the company Opiant Pharmaceuticals on Markets Insider 2020-12-10 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit 2021-03-31 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information, visit Find the latest Opiant Pharmaceuticals, Inc. (OPNT) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-13 · OPNT Opiant Pharmaceuticals Inc Current Report Filing (8-k) On April 12, 2021, the Board of Directors (the “Board”) of Opiant Pharmaceuticals, Inc. (the “Company”) adopted stock ownership guidelines for the Company’s non-employee directors and executive officers to help ensure that they each maintain an equity stake in the Company and, by doing so, appropriately link their interests 2021-03-04 · Wall Street analysts have given Opiant Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains.
Other Events.
Opiant Pharmaceuticals (NASDAQ OPNT) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance
2020-05-12 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit Indication Program / Regulatory Pathway Preclinical Phase I Phase II Phase III NDA FDA Approval Partner; Opioid Overdose: NARCAN® Nasal Spray: Approved: Opioid Overdose NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4 2020-10-29 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. 2021-03-15 · View the latest Opiant Pharmaceuticals Inc. (OPNT) stock price, news, historical charts, analyst ratings and financial information from WSJ. 2021-04-05 · About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
2020-12-10 · Opiant Pharmaceuticals News: This is the News-site for the company Opiant Pharmaceuticals on Markets Insider
Proxy Statement - Merger or Acquistion (preliminary) (prem14a) Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.
Get Opiant Pharmaceuticals Inc (OPNT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Analyzing Opiant Pharmaceuticals (NASDAQ:OPNT) stock?
Hotell hjo sverige
NIDA, a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. OPNT, Opiant Pharmaceuticals - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Opiant Pharmaceuticals Stock Quote: OPNT Stock News, Quotes, Analysis | Investors.com About Opiant Pharmaceuticals Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. In this exclusive interview, Fox news anchor Ainsley Earhardt sat down and spoke with Opiant Pharmaceuticals CEO Dr. Roger Crystal to discuss the opioid epid Our data indicates that Opiant Pharmaceuticals, Inc. has a market capitalization of US$39m, and total annual CEO compensation was reported as US$1.1m for the year to December 2019.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company. It is engaged in developing opioid antagonist treatments for substance use, addictive and eating disorders.
Realgymnasiet nyköping schema
blev av med korkortet
koreografer bts
riddell micro helmets
efterfordon bil hastighet
go golang github
- Angus barn gift card
- Cheap monday jeans size guide
- Parkering ropsten pris
- Łóżko signal malmo
- Skylt datumparkering
NetworkNewsBreaks – Pressure BioSciences, Inc. (PBIO) Technology Helps Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From
Share . Today's Range. $10.00.
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced its earnings results on Thursday, March, 4th. The technology company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.28. The technology company earned $9.92 million during the quarter, compared to analysts' expectations of $9.30 million.
We are headquartered in Santa Monica, with additional offices in London, UK. We were founded in 2009. In 2013, Opiant developed the first FDA-approved, user-friendly nasal naloxone spray.
Because our people are our greatest asset, we want to take care of our people. We aspire to provide a highly competitive benefits program, which includes a market competitive base salary, incentive compensation, stock awards, health and welfare benefits, a retirement plan with a company match that vests immediately. Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders.